162 related articles for article (PubMed ID: 10532438)
1. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation.
Hedner J; Everts B; Möller CS
Arch Ophthalmol; 1999 Oct; 117(10):1305-9. PubMed ID: 10532438
[TBL] [Abstract][Full Text] [Related]
2. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma.
Hedner J; Svedmyr N; Lunde H; Mandahl A
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S111-5. PubMed ID: 9154286
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA
Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
[TBL] [Abstract][Full Text] [Related]
5. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.
Taylor DR; Sears MR; Herbison GP; Flannery EM; Print CG; Lake DC; Yates DM; Lucas MK; Li Q
Thorax; 1993 Feb; 48(2):134-8. PubMed ID: 8493626
[TBL] [Abstract][Full Text] [Related]
6. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
7. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Kalra S; Swystun VA; Bhagat R; Cockcroft DW
Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
[TBL] [Abstract][Full Text] [Related]
8. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma.
Kraft M; Wenzel SE; Bettinger CM; Martin RJ
Chest; 1997 May; 111(5):1249-54. PubMed ID: 9149578
[TBL] [Abstract][Full Text] [Related]
9. Effect of alterations of dietary sodium on the severity of asthma in men.
Carey OJ; Locke C; Cookson JB
Thorax; 1993 Jul; 48(7):714-8. PubMed ID: 8153919
[TBL] [Abstract][Full Text] [Related]
10. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial.
Lazarus SC; Boushey HA; Fahy JV; Chinchilli VM; Lemanske RF; Sorkness CA; Kraft M; Fish JE; Peters SP; Craig T; Drazen JM; Ford JG; Israel E; Martin RJ; Mauger EA; Nachman SA; Spahn JD; Szefler SJ;
JAMA; 2001 May 23-30; 285(20):2583-93. PubMed ID: 11368732
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
Nightingale JA; Rogers DF; Barnes PJ
Chest; 2002 May; 121(5):1401-6. PubMed ID: 12006420
[TBL] [Abstract][Full Text] [Related]
12. Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye.
Sponsel WE; Mensah J; Kiel JW; Remky A; Trigo Y; Baca W; Friberg T
Am J Ophthalmol; 2000 Aug; 130(2):151-9. PubMed ID: 11004288
[TBL] [Abstract][Full Text] [Related]
13. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.
Wilson AM; Dempsey OJ; Sims EJ; Lipworth BJ
Chest; 2001 Apr; 119(4):1021-6. PubMed ID: 11296164
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
16. Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients.
Anderson WJ; Short PM; Williamson PA; Morrison AE; Palmer C; Tavendale R; Lipworth BJ
Clin Sci (Lond); 2014 Jan; 126(1):75-83. PubMed ID: 23829494
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
Medley H; Orozco S; Allen A
Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
[TBL] [Abstract][Full Text] [Related]
18. Potential masking effects of salmeterol on airway inflammation in asthma.
Mcivor RA; Pizzichini E; Turner MO; Hussack P; Hargreave FE; Sears MR
Am J Respir Crit Care Med; 1998 Sep; 158(3):924-30. PubMed ID: 9731027
[TBL] [Abstract][Full Text] [Related]
19. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol.
Konstas AG; Nakos E; Tersis I; Lallos NA; Leech JN; Stewart WC
Am J Ophthalmol; 2002 Jun; 133(6):753-7. PubMed ID: 12036665
[TBL] [Abstract][Full Text] [Related]
20. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
Wiegand L; Mende CN; Zaidel G; Zwillich CW; Petrocella VJ; Yancey SW; Rickard KA
Chest; 1999 Jun; 115(6):1525-32. PubMed ID: 10378544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
